ArticleExperimental dermatology2026
Repetin Regulates Epidermal Barrier Homeostasis and Is Associated With Inflammatory Skin Diseases.
Article in Experimental dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Repetin (RPTN) is a member of the fusion S100 protein family encoded within the epidermal differentiation complex. Although genetic studies have revealed that RPTN is a susceptibility gene for atopic dermatitis (AD), its biological function remains poorly understood. In this study, we investigated the role of RPTN in epidermal homeostasis and inflammatory skin diseases. We examined RPTN expression in normal skin, inflammatory skin diseases, and differentiated normal human keratinocytes (NHKs). Functional analyses were performed using RPTN knockdown (KD) NHK and three-dimensional (3D) skin-equivalent models. Epidermal barrier function was assessed using a lucifer yellow permeability assay, and cytokine-mediated regulation of RPTN expression was evaluated using 3D atopic dermatitis (AD) and psoriasis models. RPTN was primarily expressed in the granular layer of the normal epidermis and increased with keratinocyte differentiation. In the 3D skin-equivalent model, RPTN deficiency impaired epidermal barrier function and induced the expression of differentiation-related genes, including FLG, IVL, TGM1, CLDN1, KLK7, ALOX12, and TCHHL1. Notably, RPTN knockdown significantly increased IL-25 expression. RPTN expression was elevated in chronic atopic dermatitis (AD) lesions and in hypergranular epithelia of psoriasis vulgaris, lichen planus, and epidermolytic ichthyosis. In a 3D AD model, IL-4 and IL-13 significantly induced RPTN expression. These findings indicate that RPTN contributes to maintaining epidermal barrier homeostasis and suggest that it may be associated with regulating inflammatory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.